Aligos Therapeutics (NASDAQ:ALGS) Trading Down 2.1% – Should You Sell?

Shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) dropped 2.1% during trading on Wednesday . The company traded as low as $6.73 and last traded at $6.94. Approximately 34,079 shares traded hands during mid-day trading, a decline of 23% from the average daily volume of 44,245 shares. The stock had previously closed at $7.09.

Analyst Ratings Changes

A number of brokerages recently commented on ALGS. Wall Street Zen lowered Aligos Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. UBS Group initiated coverage on shares of Aligos Therapeutics in a report on Wednesday, January 7th. They issued a “buy” rating and a $20.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aligos Therapeutics in a report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $35.00.

Aligos Therapeutics Price Performance

The firm has a 50 day simple moving average of $8.36 and a 200-day simple moving average of $9.12. The stock has a market capitalization of $42.68 million, a price-to-earnings ratio of -0.35 and a beta of 2.66.

Hedge Funds Weigh In On Aligos Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Sio Capital Management LLC increased its holdings in shares of Aligos Therapeutics by 85.9% during the second quarter. Sio Capital Management LLC now owns 335,937 shares of the company’s stock worth $2,422,000 after buying an additional 155,217 shares in the last quarter. Woodline Partners LP acquired a new position in shares of Aligos Therapeutics in the 1st quarter worth approximately $2,602,000. Marshall Wace LLP bought a new stake in Aligos Therapeutics during the 4th quarter worth approximately $2,504,000. Readystate Asset Management LP increased its holdings in Aligos Therapeutics by 48.5% during the 3rd quarter. Readystate Asset Management LP now owns 203,113 shares of the company’s stock valued at $1,991,000 after purchasing an additional 66,331 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in Aligos Therapeutics by 22.8% in the 3rd quarter. Vanguard Group Inc. now owns 171,689 shares of the company’s stock valued at $1,683,000 after purchasing an additional 31,913 shares during the last quarter. 60.43% of the stock is currently owned by institutional investors and hedge funds.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.